101946-39-8

Basic information

• Product Name: Cyclopropanecarboxamide, N-(3-nitrophenyl)-
• CAS NO: 101946-39-8
• Molecular Formula: C10H10N2O3
• Molecular Weight: 206.201
• Mol File: 101946-39-8.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Cyclopropanecarboxamide, N-(3-nitrophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclopropanecarboxamide, N-(3-nitrophenyl)-(101946-39-8)
• EPA Substance Registry System: Cyclopropanecarboxamide, N-(3-nitrophenyl)-(101946-39-8)

Safety Data

• Hazardous Substances Data: 101946-39-8(Hazardous Substances Data)

Upstream product

• 4023-34-1 cyclopropanecarboxylic acid chloride 
• 99-09-2 3-nitro-aniline 
• 1759-53-1 cyclopropanecarboxylic acid 
• 4531-79-7 3-nitro-N-phenylaniline 

Downstream Products

• 879127-07-8 EGFR Inhibitor 
• 879127-16-9 Aurora Kinase inhibitor III 
• 879127-22-7 cyclopropanecarboxylic acid [3-(6-chloro-pyrimidin-4-ylamino)-phenyl]-amide 
• 899788-85-3 cyclopropanecarboxylic acid [3-(2-chloro-pyrimidin-4-ylamino)-phenyl]-amide 
• 899788-86-4 cyclopropanecarboxylic acid {3-[(6-chloro-pyrimidin-4-yl)-methyl-amino]-phenyl}-amide 
• 879127-21-6 N-(3-aminophenyl)-cyclopropanecarboxamide 

Relevant articles and documents

BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS

Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.

Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors

By combining the scaffolds of UI-125 and Sorafenib, a series of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine moiety were designed and synthesized as novel DFG-out B-RafV600E inhibitors. Among them, 20c-e, 20g and 21h displayed potent antiproliferative activities against melanoma A375 (B-RafV600E) cell lines with IC50 values of 3.190, 2.276, 1.856, 1.632 μM and 1.839 μM, respectively, comparable with the positive control Vemurafenib (IC50 Combining double low line 3.32 μM). Selected compounds were tested for the ERK inhibition in human melanoma A375 (B-RafV600E) and SK-MEL-2 (B-RafWT) cell lines by Western blot. The results revealed that our compounds inhibited the proliferation of melanoma A375 cells (B-RafV600E) through ERK pathway, without paradoxical activation of ERK in melanoma SK-MEL-2 cells (B-RafWT). Eventually, 20g and 21h were selected to confirm their inhibitory effects on tumor growth in A375 xenograft models in mice. Compound 20g exhibited equivalent antitumor efficacy in vivo (T/C Combining double low line 44.37%), compared to Sorafenib (T/C Combining double low line 37.35%), by 23-day repetitive administration of a single dose of 50 mg/kg without significant body weight loss.

2, 4 -DIAMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to novel pyrimide derivatives of formula (I): that are useful as kinase inhibitors. More particularly, the present invention relates to novel pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders.